Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 7/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PEPD | P12955 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11591710 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL30567640 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3052903 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL30729290 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL6679097 | 0.94 | DPP4 (0.58) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL6679094 | 0.94 | DPP4 (0.58) | DPP4DPP8DPP9DPP7ACE | |
| Trifluoroacetic Acid SCHEMBL29802195 | 0.92 | DPP4 (0.55) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15371247 | 0.91 | ACE (0.57) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL31514391 | 0.91 | ACE (0.54) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL31518648 | 0.89 | DPP4 (0.52) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116559308-A | System for non-invasive assessment of neonatal intrauterine nutritional status and use thereof | 国家卫生健康委科学技术研究所 | 2023-08-08 | — | — | CN | claimed |
| CN-113219106-B | System for non-invasive evaluation of intrauterine nutrition status of newborn and application thereof | 国家卫生健康委科学技术研究所 | 2023-01-31 | — | — | CN | claimed |
| CN-113219106-A | System for non-invasive evaluation of intrauterine nutrition status of newborn and application thereof | 国家卫生健康委科学技术研究所 | 2021-08-06 | — | — | CN | claimed |
| CN-108414660-B | Application of group of plasma metabolism small molecule markers related to early diagnosis of lung cancer | 中国药科大学 | 2020-03-20 | — | — | CN | claimed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| US-20240361326-A1 | EXOSOMAL LIPIDS AND METABOLITES FOR THE EARLY DETECTION OF HEPATOCELLULAR CARCINOMA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-20240269101-A1 | COMPOSITIONS COMPRISING MEDIUM ODD CHAIN LIPIDS WITH MULTIFUNCTIONAL ACTIVITY TO PREVENT AND TREAT SKIN INFLAMMATION AND AGING | EXCELLA BIOSCIENTIFIC LTD (IL) | 2024-08-15 | — | — | US | disclosed |
| WO-2024117176-A1 | FOOD AND DRINK COMPOSITION | 花王株式会社 | 2024-06-06 | — | — | WO | disclosed |
| EP-4373526-A1 | COMPOSITIONS AND USES OF TRIGLYCERIDE MIMETICS TO TARGET SELECTIVELY MICROBIAL LIPASE | Excella Bioscientific Ltd (IL) | 2024-05-29 | — | — | EP | disclosed |
| US-11840489-B2 | Symbiosis-promoting agent and method for promoting symbiosis of arbuscular mycorrhizal fungi | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2023-12-12 | — | — | US | disclosed |
| CN-116559308-A | System for non-invasive assessment of neonatal intrauterine nutritional status and use thereof | 国家卫生健康委科学技术研究所 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023048071-A1 | EXPRESSION PROMOTING AGENT AND FUNCTIONAL FOOD FOR MENTAL HEALTH PROMOTION | 国立大学法人九州大学 | 2023-03-30 | — | — | WO | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| US-7704957-B2 | Composition for inhibiting HIV activity extracted from Paecilomyces sp. (Tochu-kaso) J300 | RURAL DEVELOPMENT ADMINISTRATION (KR) | 2010-04-27 | — | — | US | disclosed |
| US-20040121963-A1 | Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300 | RURAL DEVELOPMENT ADMINISTRATION (KR) | 2004-06-24 | — | — | US | disclosed |
| EP-1389111-A1 | COMPOSITION FOR INHIBITING HIV ACTIVITY EXTRACTED FROM i PAECILOMYCES SP. /i (TOCHU-KASO) J300 | Republic of Korea (KR) | 2004-02-18 | — | — | EP | disclosed |
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | disclosed |
| WO-2002080921-A1 | COMPOSITION FOR INHIBITING HIV ACTIVITY EXTRACTED FROM PAECILOMYCES SP. (TOCHU-KASO) J300 | REPUBLIC OF KOREA (KR) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121963-A1 | Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300 | KMO, JMJD1C, KYAT3 | DPP4 1684/4885DPP8 3181/4885DPP9 505/4885 |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20240269101-A1 | COMPOSITIONS COMPRISING MEDIUM ODD CHAIN LIPIDS WITH MULTIFUNCTIONAL ACTIVITY TO PREVENT AND TREAT SKIN INFLAMMATION AND AGING | DGAT2, DAGLA, DGAT1 | DPP4 1459/4885DPP8 1304/4885DPP9 1183/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | DPP4 1548/4885DPP8 2179/4885DPP9 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.